OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside 
Schott Pharma Stock Rises as Barclays Upgrades Rating on Growth Outlook 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
REPAY Stock Rises After Visa Platform Connect Collaboration 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Shein Targets $26B-$27B Valuation for Hong Kong IPO 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
Alibaba Shares Fall as AI Spending Hits Profit 
 and Lead Plaintiff Deadline - March 13, 2017 - EconoTimes)
Add as a preferred source on Google
NEW YORK, Feb. 02, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NYSE:NVO) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Novo American Depositary Receipts ("ADR") between April 30, 2015 and October 27, 2016, both dates inclusive (the “Class Period”). Investors with losses in excess of $1 million are advised to join this case by visiting the firm’s site: http://www.bgandg.com/nvo.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Novo reported materially false and misleading Company earnings and predications in that they were inflated through the collusive price fixing of Novo’s insulin drugs. The Complaint also alleges that Novo misrepresented and concealed the true extent of the pricing pressures it was experiencing from pharmacy benefit managers.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/nvo or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. Investors with losses in excess of $1 million in Novo have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
